These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28982136)

  • 1. Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.
    Elliott M; Maignel J; Liu SM; Favre-Guilmard C; Mir I; Farrow P; Hornby F; Marlin S; Palan S; Beard M; Krupp J
    PLoS One; 2017; 12(10):e0185628. PubMed ID: 28982136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant botulinum neurotoxin serotype A1 in vivo characterization.
    Périer C; Martin V; Cornet S; Favre-Guilmard C; Rocher MN; Bindler J; Wagner S; Andriambeloson E; Rudkin B; Marty R; Vignaud A; Beard M; Lezmi S; Kalinichev M
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00857. PubMed ID: 34632725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").
    Pellett S; Tepp WH; Lin G; Johnson EA
    Toxicon; 2018 Jun; 147():38-46. PubMed ID: 29273248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.
    Bradshaw M; Tepp WH; Whitemarsh RC; Pellett S; Johnson EA
    Appl Environ Microbiol; 2014 Dec; 80(23):7415-22. PubMed ID: 25239905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.
    Donald S; Elliott M; Gray B; Hornby F; Lewandowska A; Marlin S; Favre-Guilmard C; Périer C; Cornet S; Kalinichev M; Krupp J; Fonfria E
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00446. PubMed ID: 30519475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of botulinum neurotoxin type D (strain 1873) in human neurons.
    Pellett S; Tepp WH; Scherf JM; Pier CL; Johnson EA
    Toxicon; 2015 Jul; 101():63-9. PubMed ID: 25937339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of immunodetection system for botulinum neurotoxin serotype E.
    Sarita R; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Indian J Med Res; 2018 Jun; 147(6):603-610. PubMed ID: 30168493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vitro detection of botulinum neurotoxin-cleaved endogenous VAMP is epitope-dependent.
    Gray B; Cadd V; Elliott M; Beard M
    Toxicol In Vitro; 2018 Apr; 48():255-261. PubMed ID: 29373835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
    Lam KH; Sikorra S; Weisemann J; Maatsch H; Perry K; Rummel A; Binz T; Jin R
    Pathog Dis; 2018 Jun; 76(4):. PubMed ID: 29688327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models.
    Elliott M; Favre-Guilmard C; Liu SM; Maignel J; Masuyer G; Beard M; Boone C; Carré D; Kalinichev M; Lezmi S; Mir I; Nicoleau C; Palan S; Perier C; Raban E; Zhang S; Dong M; Stenmark P; Krupp J
    Sci Adv; 2019 Jan; 5(1):eaau7196. PubMed ID: 30746458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
    Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
    Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and Characterization of Recombinant Botulinum Neurotoxin Serotype FA, Also Known as Serotype H.
    Hackett G; Moore K; Burgin D; Hornby F; Gray B; Elliott M; Mir I; Beard M
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29751611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.
    Yin L; Masuyer G; Zhang S; Zhang J; Miyashita SI; Burgin D; Lovelock L; Coker SF; Fu TM; Stenmark P; Dong M
    PLoS Biol; 2020 Mar; 18(3):e3000618. PubMed ID: 32182233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B.
    Masuyer G; Beard M; Cadd VA; Chaddock JA; Acharya KR
    J Struct Biol; 2011 Apr; 174(1):52-7. PubMed ID: 21078393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
    Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification and development of neutralizing antibodies from synthetic BoNT/B LC and its application in detection of botulinum toxin serotype B.
    Ponmariappan S; Jain S; Sijoria R; Tomar A; Kumar O
    Protein Pept Lett; 2012 Mar; 19(3):288-98. PubMed ID: 21933129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A).
    Kalb SR; Baudys J; Raphael BH; Dykes JK; Lúquez C; Maslanka SE; Barr JR
    Anal Chem; 2015 Apr; 87(7):3911-7. PubMed ID: 25731972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active.
    Ahmed SA; Smith LA
    J Protein Chem; 2000 Aug; 19(6):475-87. PubMed ID: 11195972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
    Arndt JW; Chai Q; Christian T; Stevens RC
    Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system.
    Villaflores OB; Hsei CM; Teng CY; Chen YJ; Wey JJ; Tsui PY; Shyu RH; Tung KL; Yeh JM; Chiao DJ; Wu TY
    J Virol Methods; 2013 Apr; 189(1):58-64. PubMed ID: 23313783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.